Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Amortization (2016 - 2025)

Historic Amortization for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to $20.8 million.

  • Evogene's Amortization fell 4806.55% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.8 million, marking a year-over-year decrease of 4806.55%. This contributed to the annual value of $21.6 million for FY2024, which is 5775.23% down from last year.
  • Evogene's Amortization amounted to $20.8 million in Q3 2025, which was down 4806.55% from $28.6 million recorded in Q2 2025.
  • Evogene's 5-year Amortization high stood at $92.8 million for Q1 2021, and its period low was -$1.9 million during Q1 2024.
  • For the 5-year period, Evogene's Amortization averaged around $22.3 million, with its median value being $1.6 million (2023).
  • In the last 5 years, Evogene's Amortization surged by 810255.68% in 2023 and then tumbled by 10388.68% in 2024.
  • Evogene's Amortization (Quarter) stood at $667000.0 in 2021, then skyrocketed by 41.23% to $942000.0 in 2022, then plummeted by 37.37% to $590000.0 in 2023, then tumbled by 99.15% to $5000.0 in 2024, then surged by 416560.0% to $20.8 million in 2025.
  • Its Amortization was $20.8 million in Q3 2025, compared to $28.6 million in Q2 2025 and -$1.8 million in Q1 2025.